Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) Nov 24, 2020
Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Nov 23, 2020
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Nov 09, 2020
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Nov 09, 2020
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Nov 06, 2020
Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Nov 04, 2020
Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting Nov 04, 2020
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Nov 04, 2020
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab Nov 02, 2020
